carbon dioxide/perflubron (S1226) / SolAeroMed - LARVOL DELTA

Laparoscopic Common Bile Duct Exploration Using a Disposable Bronchoscope. (PubMed, Indian J Surg) - "Successful LCBDE was achieved with the aid of a disposable bronchoscope for direct visualization of the biliary tract. The online version contains supplementary material available at 10.1007/s12262-022-03642-7."

Journal • Infectious Disease • Novel Coronavirus Disease

5G-Assisted Remote Guidance in Laparoscopic Simulation Training Based on 3D Printed Dry Lab Models. (PubMed, Indian J Surg) - "Perhaps in the near future, surgeons can simulate difficult operations at home or in the office, and accurately grasp the possible situations that may occur in actual operations in advance. The online version contains supplementary material available at 10.1007/s12262-022-03590-2."

Journal

Dose Response and Mechanistic Studies of a Novel Rapid Acting Bronchodilator (S1226) in a Rat Model of Acute Chronic Allergic Asthma (ATS 2022) - "The broncho-relaxant effect of CO2 was maintained at the same level in the presence of propranolol (p=0.58). S-1226® proved a rapid and effective bronchodilator following allergen challenge in the Brown Norway rat model of asthma. This effect was seen at all doses but was most pronounced at higher concentrations of CO2. There was no evidence of tachyphylaxis."

Preclinical • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Multidisciplinary Management of COVID-Associated Mucormycosis Syndemic in India. (PubMed, Indian J Surg) - "The patients with intracranial involvement have a higher chance of mortality compared to the other group. The online version contains supplementary material available at 10.1007/s12262-021-03134-0."

Journal • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia (clinicaltrials.gov) - P2; N=30; Suspended; Sponsor: SolAeroMed Inc.; Initiation date: Jun 2021 ➔ Sep 2021; Not yet recruiting ➔ Suspended

Clinical • Trial initiation date • Trial suspension • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms. (clinicaltrials.gov) - P2; N=48; Not yet recruiting; Sponsor: SolAeroMed Inc.

New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Case Series of Neurotrauma Managed by General Surgeon at Ladakh - The Highest Plateau State of India. (PubMed, Indian J Surg) - "So today, the need of hour is continuing skill enhancement training for capacity building of rural surgeon, where they are trained to do burr hole and craniotomy for reducing mortality and morbidity from neurotrauma. The online version contains supplementary material available at 10.1007/s12262-021-03002-x."

Clinical • Journal • Mood Disorders

Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia (clinicaltrials.gov) - P2; N=30; Not yet recruiting; Sponsor: SolAeroMed Inc.; Initiation date: Feb 2021 ➔ Jun 2021; Trial primary completion date: May 2021 ➔ Oct 2021

Clinical • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Safety, Tolerability and Efficacy of S-1226 in Cystic Fibrosis and Non CF Bronchiectasis (clinicaltrials.gov) - P2a; N=12; Recruiting; Sponsor: SolAeroMed Inc.; Trial completion date: Aug 2020 ➔ Aug 2022; Trial primary completion date: Apr 2020 ➔ Feb 2022

Trial completion date • Trial primary completion date • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Non‐Cystic Fibrosis Bronchiectasis • Pulmonary Disease • Respiratory Diseases

Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia (clinicaltrials.gov) - P2; N=30; Not yet recruiting; Sponsor: SolAeroMed Inc.

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

[VIRTUAL] Safe and Novel Biophysical Mucus Expectorant for Cystic Fibrosis and Non-CF Bronchiectasis: Preliminary Results from a Phase IIa Trial (ATS-I 2020) - "The preliminary efficacy results for S-1226 in CF are encouraging but will require a larger trial and longer-term treatments for evaluation. Recruitment of non-CF subjects is ongoing."

Late-breaking abstract • P2a data • Asthma • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Non‐Cystic Fibrosis Bronchiectasis • Respiratory Diseases

A Safe and Novel Biophysical Mucus Expectorant for Cystic Fibrosis and Non-CF Bronchiectasis: Preliminary Results from a Phase IIa Trial (ATS 2020) - "The preliminary efficacy results for S-1226 in CF are encouraging but will require a larger trial and longer-term treatments for evaluation. Recruitment of non-CF subjects is ongoing."

P2a data